QNCX Quince Therapeutics, Inc. logo

QNCX Quince Therapeutics, Inc.

Healthcare
$1.10+2.80%ClosedMarket Cap: $6.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.35

P/S

0.00

EV/EBITDA

0.21

DCF Value

$-2.24

FCF Yield

-647.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

1823.5%

ROA

-124.1%

ROIC

-280.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$35.9M$
Q4 null$0.00$-39.5M$
FY null$0.00$-84.0M$
Q3 null$0.00$-13.4M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy3 Hold0 Sell0 Strong Sell
D. Boral CapitalHold
2026-01-30
CitizensMarket Perform
2026-01-30
D. Boral CapitalBuy
2026-01-29
D. Boral CapitalBuy
2025-12-15
D. Boral CapitalBuy
2025-11-13

Trading Activity

Insider Trades

View All
Thye Dirkdirector, officer: CEO and CMO
SellFri Jan 23
Ryan Charles S.officer: President
SellFri Jan 23
Hannah Brendanofficer: CBO, COO & CCO
SellFri Jan 23
Senner Christopher J.director
SellWed Jan 21
McLoughlin Margaretdirector
SellWed Jan 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.45

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Peers